Editor's key points † N-methyl-D-aspartate (NMDA) dilates blood vessels in the brain. † In this study, using rat brain slices, the effect of propofol in the presence of NMDA was studied. † NMDA induces nitric oxide release but also induces superoxide. † Propofol reduced NMDA-induced dilation and decreased superoxide production. † The effect of propofol on brain microvessels may be clinically relevant.
known as one of the important systems for superoxide production in vascular pathology. 8 However, it has not been determined whether modulation of oxidative stress induced by NADPH oxidase in the brain parenchyma augments arteriolar dilatation under activation of NMDA receptors. Propofol is a clinically used i.v. anaesthetic, which maintains coupling with cerebral metabolic rate for oxygen and decreases intracranial pressure, allowing optimal intraoperative conditions during neurosurgical operations, although its effect on the cerebral microcirculation remains unclear. 9 Recent studies on cerebral parenchymal arterioles suggest that propofol decreases levels of superoxide and thus restores nitric oxide-mediated dilatation. 10 11 A recent study documented an inhibitory effect of propofol on NMDA receptor subunit phosphorylation in cultured neurones, indicating possible neuronal receptor modulation by this anaesthetic. 12 However, it has not been studied whether propofol together with oxidative stress affects regulation of cerebral microcirculation in relation to activation of neuronal receptors. Therefore, the present study was designed to examine whether NMDA induces NOS-mediated dilatation cerebral parenchymal arterioles, in addition to increased levels of superoxide induced by NADPH oxidase, and whether propofol and superoxide modulate the dilatation in relation to NMDA receptor activation.
Methods
The Institutional Review Board of Wakayama Medical University approved this study. Male Wistar rats (16 -20 weeks, n¼41) were purchased from Charles River Japan Inc. (Yokohama, Japan). Rats were deeply anaesthetized with inhalation of 3% halothane with no response to initial surgical incision. After a midline thoracotomy, 50 ml saline was infused into the left ventricle, whereas a right atrial incision was made for blood drainage. 10 11 13 -15 Brains were rapidly removed and immersed with artificial cerebrospinal fluid (control solution) of the following composition (mM): NaCl 119, KCl 4.7, CaCl 2 2.5, MgSO 4 1.17, KH 2 PO 4 1.18, NaHCO 3 25, and glucose 5.5. Whole brains were cut into blocks containing the neocortex and thereafter sectioned into coronal slices (150 mm thick) with a tissue slicer (LEICA VT 1000S; Leica Instruments GmbH, Nussloch, Germany). 10 11 13 -15 Throughout the slicing procedure, brains were immersed in the control solution. Only one protocol was used for each slice.
Live computerized videomicroscopy 10 11 13 -15 Each individual slice was then transferred to a recording chamber filled with control solution, which is attached to an inverted microscope (Olympus IX70, Tokyo, Japan). The recording system (10 ml) consisted of a recording chamber and a tubing part containing the perfusion chamber. The slices were superfused with control solution at a flow rate of 1.5 ml min 21 , bubbled with 93% O 2 +7% CO 2 (PCO 2 ¼5.3 kPa, pH¼7.4, 378C in our condition). The internal diameter of an intraparenchymal arteriole (5.4-11.1 mm in internal diameter, 13.3 -25.9 mm in external diameter) in the brain slice was continuously monitored with live computerized videomicroscopy comprising an inverted microscope, a 40× objective (Olympus), and a 2.25× video projection lens (Olympus). Identification of the arteriole in the brain slice is based on the previous studies demonstrating that the cerebral arteriole has a layer of smooth muscle cells, while the cerebral venule is composed of endothelial cells resting on a basal lamina. 10 11 14 16 17 The internal diameter of an arteriole was defined as the distance between the internal margins of walls, and changes of internal diameter in cerebral arterioles were recorded on computer image files and then they were analysed by image analysis software (PhysioTech, Tokyo, Japan respectively. The duration of each experiment was 3 h. 10 13 The amount of dilatation of the cerebral arteriole induced by vasodilators was normalized to the contraction by prostaglandin F 2 a (5×10 
Immunofluorescence analysis
In the first set of experiments, the brain was fixed with 10% formalin solution buffered with phosphate-buffered saline (PBS, pH¼7.2) and embedded in paraffin, followed by the preparation of 5 mm sections. After removing the paraffin, sections were incubated with PBS including 1% normal donkey serum and 1% bovine serum albumin to reduce nonspecific reactions. Then the sections were exposed to pairs of rabbit anti-neuronal (type I) NOS polyclonal antibodies and mouse anti-endothelial (type III) NOS monoclonal antibody at each concentration of 1 mg ml 21 at 48C, overnight. After washing, the sections were incubated with Cy3-conjugated anti-rabbit IgG and FITC-labelled anti-mouse IgG secondary antibodies (15 mg ml 21 ) at 248C for 1 h. The sections were examined using the FLUOVIEW FV300 laser scanning confocal microscope (OLYMPUS Inc., Tokyo, Japan). The negative control did not show any non-specific staining.
In the second set of experiments, the brain was fixed for 1 h in 4% paraformaldehyde, immersed in PBS (pH 7.4), dipped into TissueTek O.C.T. compound (Sakura Finetechnical, Tokyo, Japan), and stored at 2808C. Twenty micrometre sections were exposed to PBS with 0.1% Triton X-100 and incubated with PBS containing 3% donkey serum albumin to reduce non-specific reactions. The sections were further incubated with pairs of rabbit anti-neuronal NOS polyclonal antibodies (4 mg ml 21 ) and goat anti-platelet/endothelial cell adhesion molecule-1 (PECAM-1) polyclonal antibodies (4 mg ml 21 ) or mouse anti-a-smooth muscle actin monoclo- min was applied to stain nuclei. The fluorescence images were acquired using the FLUOVIEW FV300 laser scanning confocal microscope (OLYMPUS Inc.). The negative control did not show any non-specific staining.
Measurements of in situ nitric oxide and superoxide production
The membrane-permeant probe DAF-2DA or the oxidative fluorescent dye hydroethidine was used to determine levels of nitric oxide and superoxide in situ, respectively. 10 
27 M), 25 or a selective inducible NOS inhibitor 1400W (10 27 M) 26 was also applied. Brain slices, which exposed to DAF-2DA in combination with SMTC or hydroethidine in combination with Tiron (10 mM), served as the control for measurements of nitric oxide and superoxide, respectively. 10 The fluorescence in the brain slice was expressed as a ratio using these control values.
Drugs
The following pharmacological agents were used: DMSO, MK801, NMDA, propofol, or SMTC (Sigma Aldrich Inc., St Louis, MO, USA), gp91ds-tat and sgp91ds-tat (Genemed 
Statistical analysis
The data were expressed as median, inter-quartile, and full ranges. Each figure was built on data using the set of slices from the same animal. Data were evaluated using nonparametric statistical tests including the Mann -Whitney and Kruskal-Wallis tests. Differences were considered to be statistically significant when the P-value is ,0.05. (Fig. 2) . As it was shown in our previous study, 11 application of propofol 
Results

Live computerized videomicroscopy
Immunofluorescence analysis
Immunofluorescence analysis revealed distribution of neuronal NOS at the arteriolar wall and neuronal cells. The neuronal enzyme was partly localized in the distinct portion of the arteriolar wall from endothelial NOS (Fig. 3) . Co-staining for the endothelial cell marker PECAM-1 or the smooth muscle cell marker a-smooth muscle actin in addition to neuronal NOS revealed co-localization of the neuronal enzyme and endothelial or smooth muscle cells, respectively (Fig. 4) . The immunoreactivity was not recognizable when in the primary antibody absence.
Measurements of in situ nitric oxide and superoxide production pofol, or vinyl-L-NIO, but it was augmented by gp91ds-tat (Fig. 5 ). In the preliminary experiments, sgp91ds-tat did not affect increased production of nitric oxide or as superoxide 
Discussion
MK801 and the selective neuronal NOS inhibitor SMTC similarly abolished NMDA-induced dilatation, indicating the possible involvement of nitric oxide production via neuronal NOS in response to activation of NMDA receptors in cerebral parenchymal arterioles. This possibility was further suggested by the immunohistochemical analysis showing distribution of neuronal NOS at the arteriolar wall in addition to neuronal cells. The neuronal enzyme was partly localized in the distinct portion of the arteriolar wall and was distinct from endothelial NOS. Therefore, we also used co-staining with an endothelial cell marker PECAM-1 or a smooth muscle cell marker a-smooth muscle actin in addition to neuronal NOS, which revealed co-localization of the neuronal enzyme with endothelial or smooth muscle cells, respectively. In addition, MK801, SMTC, and the selective neuronal NOS inhibitor vinyl-L-NIO, but not a selective inducible (type II) NOS inhibitor, 1400W, similarly reduced levels of nitric oxide in the arteriolar wall after the addition of NMDA, indicating that the nitric oxide production by NMDA is probably via neuronal NOS. Indeed, previous studies demonstrated that NOS-immunoreactive fibres innervate cerebral arterial wall 28 and that nitric oxide derived from neuronal NOS in the perivascular region is capable of acting on microvascular smooth muscle cells. 29 Our model adds to previous studies in isolated microvessels and whole animals in terms of evaluating the cerebral microcirculation when neuronal -vascular interactions are preserved. However, the results might be affected by our study design using brain slice preparation. 30 Our study together with previous studies may support a role of nitric oxide from neuronal NOS as a critical link between NMDA receptor-activation and cerebral blood flow in vivo. 31 Indeed, previous in vivo studies also demonstrated that NMDA (10 27 to 10 25 M), similarly to glutamate, induces pial arteriolar dilatation via neuronal NOS. 32 However, we cannot completely rule out the involvement of endothelial NOS in the dilation to NMDA in our study, although neuronal NOS inhibitors used in the current study are highly selective towards the neuronal enzyme. 19 25 In the current study, gp91ds-tat or Tiron similarly augmented NMDA-induced arteriolar dilatation and gp91ds-tat increased levels of nitric oxide, whereas both compounds inhibited superoxide within the cerebral arteriole. Tiron is a superoxide antagonist, 22 and gp91ds-tat is a highly selective NADPH oxidase inhibitor, especially towards Nox2. 8 20 21 Therefore, these results suggest that NMDA augments superoxide production in the brain parenchymal arterioles via NADPH oxidase as it was shown by previous studies using neuronal tissues. 427 In addition, there is a possibility that superoxide captures a portion of nitric oxide produced by NOS under activation of NMDA receptors, reducing dilatation of the brain parenchymal arteriole. 33 Our study also indicates a possible role of Nox2 in the superoxide production induced by NMDA in the cerebral microcirculation. Indeed, activation of Nox2 via NMDA receptors has been confirmed in the brain in recent studies. 5 7 Propofol attenuated NMDA-induced dilatation in accordance with decreased production of nitric oxide in the cerebral parenchymal arteriole. A recent study has documented an inhibitory effect of propofol on NMDA receptor subunit phosphorylation in cultured neurones, indicating possible receptor regulation by this anaesthetic in the brain. 12 However, it is unclear whether the inhibition of phosphorylation on NMDA receptor subunits contributes to the inhibitory effect of propofol on cerebral vasodilatation. Further studies are needed to clarify this point. It is also crucial to note that in our study, propofol decreased the level of nitric oxide to a similar extent to that seen in arterioles treated with SMTC or vinyl-L-NIO. Propofol probably reduces production of nitric oxide related to neuronal NOS activation via NMDA receptors, resulting in impairment of dilatation of cerebral parenchymal arterioles. In humans, plasma concentrations of propofol in the clinical practice were reportedly up to 6×10 25 M. 34 -36 Therefore, effective concentrations of propofol to reduce arteriolar dilatation in response to NMDA in the current study are within the clinical range given the plasmafree concentrations calculated from its plasma protein binding (up to 98%). 35 In this study, propofol reduced levels of superoxide when NMDA was added and this is in agreement with our recent study demonstrating that propofol lowers levels of superoxide as a NADPH oxidase inhibitor in the brain slice preparations. 10 11 However, propofol's effect on cerebral arteriolar tone by the reduction of oxidative stress seems negligible under activation of NMDA receptors, since it appears to be an inhibitor of the NMDA receptorrelated pathway. 12 Augmented expression of NMDA receptors corresponding with increased superoxide production in the brain has been shown after cerebral ischaemia of animal models. 7 37 The involvement of NMDA receptor activation in adverse neurological outcome was also documented in some surgical patients. 38 Therefore, it can be concluded that oxidative stress via NMDA receptors is one of the important determinants to predict neurological outcome after a brain insult. It is also crucial to note the conclusions from previous studies using gene-disrupted mice that neuronal NOS activity is critical to induce brain damage after focal and global cerebral ischaemia, although the activity plays a role in increased cerebral capillary blood flow response to hypoxia. 39 40 In addition, previous studies documented that propofol is neuroprotective in animal models of cerebral ischaemia, both in vitro and in vivo. 41 These results, together with our study, may support the current concept that propofol reduces cerebral blood flow but maintains coupling with cerebral metabolic rate for oxygen, and that it decreases intracranial pressure, resulting in optimal intraoperative conditions during neurosurgical operations. 9 
Conclusions
NMDA dilates the cerebral parenchymal arterioles possibly via neuronal NOS activation, whereas it produces superoxide via NADPH oxidase. In these arterioles, propofol within clinically relevant concentrations reduces both dilatation and superoxide production in response to NMDA. NMDA receptors appear to play a role in cerebral microvessel dilatation mediated by neuronal activation, whereas propofol and oxidative stress may modulate this dilatation in the clinical condition. However, the clinical significance of the modulation in cerebral vascular function by the use of propofol is *Difference between the brain slices treated with the sole NMDA and the brain slices treated with NMDA in combination with MK801, SMTC, gp91ds-tat, propofol, or vinyl-L-NIO is statistically significant (P,0.05). Data were from 10 rats.
still unclear and further studies are warranted to clarify this point.
